

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 March 2011 (31.03.2011)

(10) International Publication Number
WO 2011/036167 A1

PCT

(51) International Patent Classification:

A61K 31/198 (2006.01) *A61P 25/16* (2006.01)
A61P 25/14 (2006.01)

(21) International Application Number:

PCT/EP2010/063946

(22) International Filing Date:

22 September 2010 (22.09.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/244,658 22 September 2009 (22.09.2009) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DI PAOLO, Thérèse** [CA/CA]; Molecular Endocrinology and Oncology Research Center, Laval University Medical Center, CHUL, 2705 Laurier Boulevard, Québec, Québec G1V 4G2 (CA). **FEUERBACH, Dominik** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **GOMEZ-MANCILLA, Baltazar** [MX/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **JOHNS, Donald** [US/US]; Novartis Institutes for BioMedical Research, Inc., 220 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).

(74) Agent: **WIESSNER, Michael**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS

(57) Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.



WO 2011/036167 A1

- 1 -

Use of nicotinic acetylcholine receptor alpha 7 activators

The present invention relates to pharmaceutical uses of nicotinic acetylcholine receptor alpha 7 ($\alpha 7$ -nAChR) activators, i.e. $\alpha 7$ -nAChR agonists or positive allosteric modulators.

Parkinson's Disease (PD) is a chronic and progressive degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. Characteristics of Parkinson's Disease are varied and include one or more of the following: tremor, rigidity, bradykinesia, akinesia, gait and postural disturbances, postural instability, speech and swallowing disturbances and cognitive impairment (e.g. memory loss, dementia and slowed reaction times). PD is thought to be the direct result of the loss of dopamine-producing cells in the substantia nigra. More than 60,000 new cases of PD are diagnosed in the USA alone each year.

The most commonly used treatment for PD is dopamine agonist therapy, for example by administration of L-dopa (levodopa) in combination with a decarboxylase inhibitor (e.g. carbidopa). However, for many patients, a long term dopamine agonist therapy causes involuntary movements (dyskinesias) as a significant side effect (for review: Fabbrini et al, Movement Disorders, 2007, 22(10), 1379-1389; Konitsiotis, Expert Opin Investig Drugs, 2005, 14(4), 377-392; Brown et al, IDrugs, 2002, 5(5), 454-468). Consequently, there is a need for effective regimes for inhibiting or treating dyskinesia, which can be carried out without adversely affecting anti-PD treatments.

Compounds described as $\alpha 7$ -nAChR agonists or $\alpha 7$ -nAChR positive allosteric modulators have been described in, e.g. WO2001/85727, WO2004/022556, WO2005/118535, WO2005/123732, WO2006/005608, WO2007/045478, WO2007/068476, WO2007/068475 and Haydar et al (Current Topics in Medicinal Chemistry, 2010, 10, 144-152).

It has been found that $\alpha 7$ -nAChR agonists or $\alpha 7$ -nAChR positive allosteric modulators may be used in the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in PD. In particular, it has been found that $\alpha 7$ -nAChR agonists or $\alpha 7$ -nAChR positive allosteric modulators may be used in the treatment, prevention or delay

- 2 -

of progression of said dyskinesia, wherein the therapy comprises the administration of levodopa.

Accordingly, a first aspect of the invention concerns the use of a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator for the treatment (whether therapeutic or prophylactic), prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

One embodiment of said first aspect concerns the use of a $\alpha 7$ -nAChR agonist for the treatment (whether therapeutic or prophylactic), prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

Another embodiment of said first aspect concerns the use of a $\alpha 7$ -nAChR positive allosteric modulator for the treatment (whether therapeutic or prophylactic), prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator.

One embodiment of said further aspect relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR agonist.

Another embodiment of said further aspect relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR positive allosteric modulator.

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises (i) diagnosing dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in said subject and (ii) administering

- 3 -

to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator.

One embodiment of said further aspect relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises (i) diagnosing dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in said subject and (ii) administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR agonist.

Another embodiment of said further aspect relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises (i) diagnosing dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in said subject and (ii) administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR positive allosteric modulator.

A further aspect of the invention relates to a pharmaceutical composition comprising a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

One embodiment of said further aspect relates to a pharmaceutical composition comprising a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

Another embodiment of said further aspect relates to a pharmaceutical composition comprising a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

A further aspect of the invention relates to the use of a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator for the manufacture of a medicament for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

One embodiment of said further aspect relates to the use of a $\alpha 7$ -nAChR agonist for the manufacture of a medicament for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

- 4 -

Another embodiment of said further aspect relates to the use of a $\alpha 7$ -nAChR positive allosteric modulator for the manufacture of a medicament for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

Nicotinic acetylcholine receptor alpha 7 agonist:

As used herein a " $\alpha 7$ -nAChR agonist" is a compound that binds to a receptor comprising a $\alpha 7$ -nAChR subunit in vivo and in vitro and is activating the receptor to perform its physiological function. Activation can be measured by the method disclosed in WO2001/85727, i.e. a functional affinity assay at the homomeric alpha 7 nicotinic acetylcholine receptor ($\alpha 7$ nAChR) carried out with a rat pituitary cell line stably expressing the $\alpha 7$ nAChR. As read out, the calcium influx upon stimulation of the receptor compared to epibatidine is used. " $\alpha 7$ -nAChR agonists" according to the invention typically induce calcium influx of at least 50% of the maximal influx evoked by epibatidine with an EC_{50} value of at least 1 μM ; preferred agonists induce calcium influx of at least 75% of the maximal influx evoked by epibatidine with an EC_{50} value of at least 400 nM; more preferred agonists induce calcium influx of at least 85% of the maximal influx evoked by epibatidine with an EC_{50} value of at least 50 nM.

In particular, preferred $\alpha 7$ -nAChR agonists should be well absorbed from the gastrointestinal tract, should be sufficiently metabolically stable and possess favorable pharmacokinetic properties.

Further preferred $\alpha 7$ -nAChR agonists bind in-vivo potently to $\alpha 7$ -nAChRs whilst showing little affinity for other receptors, especially for other nAChRs, e.g. $\alpha 4\beta 2$ nAChR, for muscarinic acetylcholine receptors, e.g. M1, and/or the 5-HT₃ receptor.

Further preferred $\alpha 7$ -nAChR agonists cross the blood brain barrier effectively.

Preferred $\alpha 7$ -nAChR agonists should be non-toxic and demonstrate few side-effects.

Furthermore, a preferred $\alpha 7$ -nAChR agonist will be able to exist in a physical form that is stable, non-hygroscopic and easily formulated.


In one embodiment, the $\alpha 7$ -nAChR agonist is selective for a receptor comprising a $\alpha 7$ -nAChR subunit, since such an agonist would be expected to cause fewer side effects than a non-selective agonist to a treated subject. An agonist being selective for a receptor

- 5 -

comprising a $\alpha 7$ -nAChR subunit has a functional affinity to such a receptor to a much higher degree, e.g. at least 10-fold affinity difference in EC_{50} value, preferably at least 20-fold, more preferably at least 50-fold, compared to any other nicotinic acetylcholine receptor. To assess the affinity of the $\alpha 7$ -nAChR agonists of the invention on other nicotinic acetylcholine receptors, the method disclosed in WO2001/85727 can be used, i.e. to assess the affinity on human neuronal $\alpha 4\beta 2$ nAChR, a similar functional assay is carried out using a human embryonic kidney cell line stable expressing the human $\alpha 4\beta 2$ subtype and to assess the activity of the compounds of the invention on the "ganglionic subtype" and the "muscle type" of nicotinic receptor, similar functional assays are carried out with a human embryonic kidney cell line stably expressing the human "ganglionic subtype" or a cell line endogenously expressing the human "muscle type" of nicotinic receptors.

In the last 15 years much effort has been focused on developing selective $\alpha 7$ nAChR agonists leading to the discovery of many different chemotypes displaying said selective activity. These efforts are summarized the review from Horenstein et al (Mol Pharmacol, 2008, 74, 1496-1511, which describes no less than 9 different families of $\alpha 7$ nAChR agonists, in most of which selective agonists have been found. All compounds disclosed in figure 1 of said review are incorporated herein by reference. In fact, several drug candidates having an $\alpha 7$ nAChR agonist mode of action entered pre-clinical or even clinical testing (for review: Broad et al, Drugs of the Future, 2007, 32(2), 161-170; Romanelli et al, Expert Opin Ther Patents, 2007, 17(11), 1365-1377). Examples of such compounds – again belonging to a diversity of chemotypes - are MEM3454, MEM63908, SSR180711, GTS21, EVP6124, ABT107, ABT126, TC-5619, AZD-6319 and SAR-130479. Further $\alpha 7$ nAChR agonists and their use as pharmaceuticals are known, for example, from WO2001/85727, WO2004/022556, WO2005/118535, WO2005/123732, WO2006/005608, WO2007/045478, WO2007/068476 and WO2007/068475.

In one embodiment, the $\alpha 7$ -nAChR agonist is a compound of formula (I)




wherein

L_1 is $-CH_2-$; L_2 is $-CH_2-$ or $-CH_2-CH_2-$; and L_3 is $-CH_2-$ or $-CH(CH_3)-$; or

- 6 -

L₁ is $-\text{CH}_2-\text{CH}_2-$; L₂ is $-\text{CH}_2-$; and L₃ is $-\text{CH}_2-\text{CH}_2-$;

L₄ is a group selected from



L4a


L4b

wherein the bond marked with the asterisk is attached to the azabicycloalkyl moiety;

R₁ is hydrogen or C₁₋₄alkyl;

X₁ is $-\text{O}-$ or $-\text{NH}-$;

A₂ is selected from



wherein the bond marked with the asterisk is attached to X₁;

A₁ is a five- to ten-membered monocyclic or fused polycyclic aromatic ring system which may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein the ring system may contain not more than 2 oxygen atoms and not more than 2 sulfur atoms, and wherein the ring system may be substituted once or more than once by R₂, and wherein a substituent on a nitrogen in a heterocyclic ring system may not be halogen;

each R₂ independently is C₁₋₆alkyl, C₁₋₆halogenalkyl, C₁₋₆alkoxy, C₁₋₆halogenalkoxy, halogen, cyano or a three- to six-membered monocyclic ring system which may be aromatic, saturated or partially saturated and which may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, and wherein each ring system may contain not more than 2 oxygen atoms and not more than 2 sulfur atoms, and wherein each ring system may in turn be substituted once or more than once by C₁₋₆alkyl, C₁₋₆halogenalkyl, C₁₋₆alkoxy, C₁₋₆halogenalkoxy, halogen or cyano, and wherein a substituent on a nitrogen in a heterocyclic ring system may not be halogen;


or two R₂ at adjacent ring atoms form a C₃₋₄alkylene group, wherein 1-2 carbon atoms may be replaced by X₂, and wherein the C₃₋₄alkylene group may be substituted once or more than once by R₃;

each X₂ independently is $-\text{O}-$ or $-\text{N}(\text{R}_4)-$;

- 7 -

each R_4 independently is hydrogen or C_{1-6} alkyl; and
 each R_3 independently is halogen or C_{1-6} alkyl;
 in free base form or in acid addition salt form.

In one embodiment, the $\alpha 7$ -nAChR agonist is a compound of formula (II)



(II),

wherein

A_3 is a five- to ten-membered monocyclic or fused polycyclic aromatic ring system which may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein the ring system may contain not more than 2 oxygen atoms and not more than 2 sulfur atoms, and wherein the ring system may be substituted once or more than once by R_5 , and wherein a substituent on a nitrogen in a heterocyclic ring system may not be halogen;

each R_5 independently is C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{1-6} alkoxy, C_{1-6} halogenalkoxy, halogen, cyano, amino or a three- to six-membered monocyclic ring system which may be aromatic, saturated or partially saturated and which may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, and wherein each ring system may contain not more than 2 oxygen atoms and not more than 2 sulfur atoms, and wherein each ring system may in turn be substituted once or more than once by C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{1-6} alkoxy, C_{1-6} halogenalkoxy, halogen or cyano, and wherein a substituent on a nitrogen in a heterocyclic ring system may not be halogen;

or two R_5 at adjacent ring atoms form a C_{3-4} alkylene group, wherein 1-2 carbon atoms may be replaced by X_3 , and wherein the C_{3-4} alkylene group may be substituted once or more than once by R_6 ;

each X_3 independently is $-O-$ or $-N(R_7)-$;

each R_7 independently is hydrogen or C_{1-6} alkyl; and

each R_6 independently is halogen or C_{1-6} alkyl;

in free base form or in acid addition salt form.

- 8 -

Unless indicated otherwise, the expressions used in this invention have the following meaning:

"Alkyl" represents a straight-chain or branched-chain alkyl group, for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, n-pentyl, n-hexyl; C₁₋₆alkyl preferably represents a straight-chain or branched-chain C₁₋₄alkyl with particular preference given to methyl, ethyl, n-propyl, iso-propyl and tert-butyl.

Each alkyl part of "alkoxy", "halogenalkyl" and so on shall have the same meaning as described in the above-mentioned definition of "alkyl", especially regarding linearity and preferential size.

A substituent being substituted "once or more than once", for example as defined for A₁, is preferably substituted by one to three substituents.

Halogen is generally fluorine, chlorine, bromine or iodine; preferably fluorine, chlorine or bromine. Halogenalkyl groups preferably have a chain length of 1 to 4 carbon atoms and are, for example, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 2-fluoroethyl, 2-chloroethyl, pentafluoroethyl, 1,1-difluoro-2,2,2-trichloroethyl, 2,2,2-trichloroethyl, 1,1,2,2-tetrafluoroethyl, 2,2,3,3-tetrafluoropropyl, 2,2,3,3,3-pentafluoropropyl or 2,2,3,4,4,4-hexafluorobutyl; preferably -CF₃, -CHF₂, -CH₂F, -CHF-CH₃, -CF₂CH₃, or -CH₂CF₃.

In the context of the invention, the definitions of "two R₂ at adjacent ring atoms form a C₃₋₄alkylene group, wherein 1-2 carbon atoms may be replaced by X₂" or "two R₅ at adjacent ring atoms form a C₃₋₄alkylene group, wherein 1-2 carbon atoms may be replaced by X₃" encompass -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -O-CH₂-O-, -O-CH₂-CH₂-O- and -CH₂-CH₂-NH-. An example of a substituted group is -CH₂-CH₂-N(CH₃)-

In the context of the invention, the definition of A₁ or A₃ as a "five- to ten-membered monocyclic or fused polycyclic aromatic ring system" encompasses a C₆- or C₁₀-aromatic hydrocarbon group or a five- to ten-membered heterocyclic aromatic ring system.

"Polycyclic" means preferably bicyclic.

In the context of the invention, the definition of R_2 as a "three- to six-membered monocyclic ring system" encompasses a C_6 -aromatic hydrocarbon group, a five- to six-membered heterocyclic aromatic ring system and a three- to six-membered monocyclic aliphatic or heterocyclic ring system.

A C_6 - or C_{10} -aromatic hydrocarbon group is typically phenyl or naphthyl, especially phenyl.


Preferably, but also depending on substituent definition, "five- to ten-membered heterocyclic aromatic ring systems" consist of 5 to 10 ring atoms of which 1-3 ring atoms are hetero atoms. Such heterocyclic aromatic ring systems may be present as a single ring system or as bicyclic or tricyclic ring systems; preferably as single ring systems or as benz-annelated ring systems. Bicyclic or tricyclic ring systems may be formed by annelation of two or more rings, or by a bridging atom, e.g. oxygen, sulfur, nitrogen. Examples of heterocyclic ring systems are: imidazo[2,1-b]thiazole, pyrrole, pyrroline, pyrrolidine, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline, imidazolidine, triazole, triazoline, triazolidine, tetrazole, furane, dihydrofurane, tetrahydrofurane, furazane (oxadiazole), dioxolane, thiophene, dihydrothiophene, tetrahydrothiophene, oxazole, oxazoline, oxazolidine, isoxazole, isoxazoline, isoxazolidine, thiazole, thiazoline, thiazolidine, isothiazole, isothiazoline, isothiazolidine, thiadiazole, thiadiazoline, thiadiazolidine, pyridine, piperidine, pyridazine, pyrazine, piperazine, triazine, pyrane, tetrahydropyrane, thiopyrane, tetrahydrothiopyrane, oxazine, thiazine, dioxine, morpholine, purine, pteridine, and the corresponding benz-annelated heterocycles, e.g. indole, isoindole, coumarin, isoquinoline, quinoline and the like. Preferred heterocycles are: imidazo[2,1-b]thiazole, oxazole, isoxazole, thiazole, isothiazole, triazole, pyrrole, furane, tetrahydrofurane, pyridine, pyrimidine, imidazole or pyrazole.

In the context of the invention, three- to six-membered monocyclic aliphatic ring systems are typically cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

On account of asymmetrical carbon atom(s) that may be present in the compounds of formula (I) and compounds of formula (II), the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures or diastereomeric mixtures. All optical isomers and their mixtures, including racemic mixtures, are part of the present invention.

- 10 -


In one embodiment, the $\alpha 7$ -nAChR agonist is a compound of formula (I)



wherein

L_1 is $-\text{CH}_2-$; L_2 is $-\text{CH}_2\text{-CH}_2-$; and L_3 is $-\text{CH}_2-$ or $-\text{CH}(\text{CH}_3)-$;

L_4 is a group selected from



L4a


L4b

wherein the bond marked with the asterisk is attached to the azabicycloalkyl moiety;

R_1 is hydrogen or C_{1-4} alkyl;

X_1 is $-\text{O}-$ or $-\text{NH}-$;


A_2 is selected from



wherein the bond marked with the asterisk is attached to X_1 ;

A_1 is a five- to ten-membered monocyclic or fused polycyclic aromatic ring system which may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein the ring system may contain not more than 2 oxygen atoms and not more than 2 sulfur atoms, and wherein the ring system may be substituted once or more than once by R_2 , and wherein a substituent on a nitrogen in a heterocyclic ring system may not be halogen; and each R_2 independently is C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{1-6} alkoxy, C_{1-6} halogenalkoxy or halogen.

In one embodiment, the $\alpha 7$ -nAChR agonist is a compound of formula (I)




- 11 -

wherein

L_1 is $-\text{CH}_2-$; L_2 is $-\text{CH}_2\text{CH}_2-$; and L_3 is $-\text{CH}_2-$;

L_4 is




L4a

wherein the bond marked with the asterisk is attached to the azabicycloalkyl moiety;

R_1 is hydrogen or C_{1-4} alkyl;

A_1 is a five- to ten-membered monocyclic or fused polycyclic aromatic ring system which may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein the ring system may contain not more than 2 oxygen atoms and not more than 2 sulfur atoms, and wherein the ring system may be substituted once or more than once by R_2 , and wherein a substituent on a nitrogen in a heterocyclic ring system may not be halogen; and each R_2 independently is C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{1-6} alkoxy, C_{1-6} halogenalkoxy or halogen.


In one embodiment, the $\alpha 7$ -nAChR agonist is a compound of formula (I)



wherein

L_1 is $-\text{CH}_2-$; L_2 is $-\text{CH}_2\text{CH}_2-$; and L_3 is $-\text{CH}_2-$ or $-\text{CH}(\text{CH}_3)-$;

L_4 is




L4b

wherein the bond marked with the asterisk is attached to the azabicycloalkyl moiety;

X_1 is $-\text{O}-$ or $-\text{NH}-$;

A_2 is selected from


- 12 -



wherein the bond marked with the asterisk is attached to X_1 ;

A_1 is a five- to ten-membered monocyclic or fused polycyclic aromatic ring system which may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein the ring system may contain not more than 2 oxygen atoms and not more than 2 sulfur atoms, and wherein the ring system may be substituted once or more than once by R_2 , and wherein a substituent on a nitrogen in a heterocyclic ring system may not be halogen; and each R_2 independently is C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{1-6} alkoxy, C_{1-6} halogenalkoxy or halogen.


In one embodiment, the $\alpha 7$ -nAChR agonist is a compound of formula (I)



wherein

L_1 is $-\text{CH}_2-\text{CH}_2-$; L_2 is $-\text{CH}_2-$; and L_3 is $-\text{CH}_2-\text{CH}_2-$;

L_4 is




L4b

wherein the bond marked with the asterisk is attached to the azabicycloalkyl moiety;

X_1 is $-\text{O}-$ or $-\text{NH}-$;

A_2 is selected from




wherein the bond marked with the asterisk is attached to X_1 ;

- 13 -

A₁ is a five- to ten-membered monocyclic or fused polycyclic aromatic ring system which may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein the ring system may contain not more than 2 oxygen atoms and not more than 2 sulfur atoms, and wherein the ring system may be substituted once or more than once by R₂, and wherein a substituent on a nitrogen in a heterocyclic ring system may not be halogen; and each R₂ independently is C₁₋₆alkyl, C₁₋₆halogenalkyl, C₁₋₆alkoxy, C₁₋₆halogenalkoxy or halogen.

In one embodiment, the α7-nAChR agonist is a compound of formula (II)



wherein

A₃ is a five- to ten-membered monocyclic or fused polycyclic aromatic ring system which may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein the ring system may contain not more than 2 oxygen atoms and not more than 2 sulfur atoms, and wherein the ring system may be substituted once or more than once by R₅, and wherein a substituent on a nitrogen in a heterocyclic ring system may not be halogen; and each R₅ independently is C₁₋₆alkyl, C₁₋₆halogenalkyl, C₁₋₆alkoxy, C₁₋₆halogenalkoxy, amino or halogen.


In one embodiment, the α7-nAChR agonist is a compound selected from Group P1; Group P1 is the group consisting of

- A-1: (S)-(1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-(2-fluoro-phenyl)-ethyl ester;
- A-2: (R)-(1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (R)-1-(2-chloro-phenyl)-ethyl ester;
- A-3: (S)-(1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-phenyl-ethyl ester;
- B-1: (R)-3-(5-phenyl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane;
- B-2: (R)-3-(5-p-tolyl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane;
- B-3: (R)-3-(5-(2-fluoro-4-methyl-phenyl)-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane;
- B-4: (R)-3-(5-(3,4-dimethyl-phenyl)-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane;
- B-5: (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;

- B-6: (R)-3-(6-phenyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;
B-7: (R)-3-(6-(3,4-dimethyl-phenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;
B-8: (R)-3-[6-(2-fluoro-4-methyl-phenyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
B-9: (R)-3-[6-(4,5-dimethyl-2-fluoro-phenyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
B-10: (R)-3-[6-(3,4-dimethyl-phenyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
B-11: (R)-3-[6-(4-methyl-phenyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
B-12: (R)-3-[6-(2,5-difluoro-4-methyl-phenyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
B-13: (2S,3R)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;
B-14: (2R,3S)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;
B-15: (2S,3R)-3-[5-(1H-indol-5-yl)-pyrimidin-2-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;
B-16: (2R,3S)-3-[5-(1H-indol-5-yl)-pyrimidin-2-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;
B-17: 3-[6-(1H-indol-5-yl)-pyridin-3-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;
B-18: (2S,3R)-2-methyl-3-[6-(5-methyl-thiophen-2-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
B-19: 3-[6-(2,3-dimethyl-1H-indol-5-yl)-pyridazin-3-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;
B-20: trans-2-methyl-1-aza-bicyclo[2.2.2]oct-3-yl)-(6-phenyl-pyridin-3-yl)-amine;
B-21: trans-[6-(1H-indol-5-yl)-pyridin-3-yl]-(2-methyl-1-aza-bicyclo[2.2.2]oct-3-yl)-amine;
C-1: (4S,5R)-4-[5-(1H-indol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane;
C-2: 5-{2-[(4S,5R)-(1-aza-bicyclo[3.3.1]non-4-yl)oxy]-pyrimidin-5-yl}-1,3-dihydro-indol-2-one;
C-3: (4S,5R)-4-[6-(1H-indol-5-yl)-pyridin-3-yloxy]-1-aza-bicyclo[3.3.1]nonane;
C-4: (4S,5R)-4-[5-(1H-indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane;
C-5: (4S,5R)-4-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[3.3.1]nonane;
C-6: 5-{6-[(4S,5R)-(1-aza-bicyclo[3.3.1]non-4-yl)oxy]-pyridazin-3-yl}-1,3-dihydro-indol-2-one;
C-7: (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1H-indol-5-yl)-pyridin-2-yl]-amine;
C-8: (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1H-indol-5-yl)-pyrimidin-2-yl]-amine;
C-9: (1-aza-bicyclo[3.3.1]non-4-yl)-[6-(1H-indol-5-yl)-pyridin-3-yl]-amine;
C-10: (1-aza-bicyclo[3.3.1]non-4-yl)-[6-(1H-indol-5-yl)-pyridin-3-yl]-amine;
C-11: (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1H-indol-4-yl)-pyrimidin-2-yl]-amine;
C-12: (1-aza-bicyclo[3.3.1]non-4-yl)-[6-(1H-indol-5-yl)-pyridazin-3-yl]-amine;
D-1: 5-benzofuran-5-ylethynyl-1-methyl-3-piperidin-1-ylmethyl-pyrrolidin-2-one;
D-2: 1-methyl-5-phenylethynyl-3-piperidin-1-ylmethyl-pyrrolidin-2-one;
D-3: 1-methyl-5-(1-methyl-1H-indol-5-ylethynyl)-3-piperidin-1-ylmethyl-pyrrolidin-2-one;
D-4: 5-(3-Amino-phenylethynyl)-1-methyl-3-piperidin-1-ylmethyl-pyrrolidin-2-one;

- 15 -

E-1: 4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.1^{3,7}]decane having the formula




E-1a: (4S)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.1^{3,7}]decane;

E-1b: 4-(6-(1H-indol-5-yl)-pyridazin-3-yloxy)-1azatricyclo[3.3.1.1^{3,7}]decane;


E-1c: 4-(6-(1H-indol-5-yl)-pyridin-3-yloxy)-1azatricyclo[3.3.1.1^{3,7}]decane;

E-1d: 4-(5-(1H-indol-5-yl)-pyrimidin-2-yloxy)-1azatricyclo[3.3.1.1^{3,7}]decane;

E-2: 2-(6-phenylpyridazine-3-yl)octahydropyrrolo[3,4-c]pyrrole having the formula




E-3: 5-[6-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-pyridazin-3-yl]1H-indole having the formula




E-3a: 5-[6-(cis-5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-pyridazin-3-yl]1H-indole;

E-4: 5-[5-(6-methyl-3,6-diaza-bicyclo[3.2.0]hept-3-yl)-pyridin-2-yl]-1H-indole having the formula



E-4a: 5-[5-((1R,5R)-6-methyl-3,6-diaza-bicyclo[3.2.0]hept-3-yl)-pyridin-2-yl]-1H-indole

E-5: 2-Methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole having the formula



E-6: 5-[6-[1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl]-1H-indole;

E-6a: 5-[6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl]-1H-indole;

E-7: 5-[6-[1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl]-1,3-dihydro-indol-2-one;


E-7a: 5-[6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl]-1,3-dihydro-indol-2-one;

E-8: N-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide;

E-8a: N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide

- E-8b: N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
- E-9: N-(1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
- E-9a: N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
- E-9b: N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
- E-10: N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide;
- E-10a: (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide;
- E-11: N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide;
- E-11a: (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide;
- E-11b: N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide;
- E-11c: (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide;
- E-11d: N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-pyridinyl)thiophene-2-carboxamide;
- E-11e: (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-pyridinyl)thiophene-2-carboxamide;
- E-12: 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
- E-13: [N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)]-4-chlorobenzamide;
- E-14: furo[2,3-c]pyridine-5-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;
- E-15: 2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;
- E-16: 5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide;
- E-17: N-{4-[4-(2,4-dimethoxy-phenyl)-piperazin-1-yl]-butyl}-4-pyridin-2-yl-benzamide;
- E-18: 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl)-urea;
- E-19: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino-(2,3-h)(3)-benzazepine;
- E-20: (2'R)-spiro-[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
- E-21: 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-bromo-phenyl ester;
- E-22: 3-[1-(2,4-Dimethoxy-phenyl)-meth-(E)-ylidene]-3,4,5,6-tetrahydro-[2,3']bipyridinyl;
- E-23: 7-(2-Methoxy-phenyl)-benzofuran-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;
- E-24: N-methyl-1-{5-[3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-furo[2,3-b]pyridin]-5'-yl]-2-thienyl}methanamine having the formula

- 17 -



E-24a: N-methyl-1-{5-[(2R)-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-furo[2,3-b]pyridin]-5'-yl]-2-thienyl}methanamine;

E-24b: N-methyl-1-{5-[(2S)-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-furo[2,3-b]pyridin]-5'-yl]-2-thienyl}methanamine;

E-25a: 6-[(Anilinoacarbonyl)amino]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamide;

E-25b: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(4-chlorophenyl) amino]carbonyl]amino)-1-benzothiophene-2-carboxamide;

E-25c: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(2-methoxyphenyl)amino]carbonyl]-amino)-1-benzothiophene-2-carboxamide;

E-25d: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(4-methoxyphenyl)amino]carbonyl]-amino)-1-benzothiophene-2-carboxamide;

E-25e: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(2-phenylethyl)amino]carbonyl]amino)-1-benzothiophene-2-carboxamide;

E-25f: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(3-cyanophenyl)amino]carbonyl]amino)-1-benzothiophene-2-carboxamide;

E-25g: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(3-bromophenyl)amino]carbonyl]amino)-1-benzothiophene-2-carboxamide;

E-25h: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(2-ethoxyphenyl)amino]carbonyl]amino)-1-benzothiophene-2-carboxamide;

E-25i: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(4-(dimethylamino)phenyl)amino]carbonyl]amino)-1-benzothiophene-2-carboxamide;

E-25j: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(2-nitrophenyl)amino]carbonyl]amino)-1-benzothiophene-2-carboxamide;

E-25k: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(2,6-difluorophenyl)amino]carbonyl]-amino)-1-benzothiophene-2-carboxamide;

E-25l: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(2,4-dichlorophenyl)amino]carbonyl]-amino)-1-benzothiophene-2-carboxamide;

E-25m: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(3-(trifluoromethyl)phenyl)amino]carbonyl]amino)-1-benzothiophene-2-carboxamide;

- E-25n: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(3,4,5-trimethoxyphenyl)amino]carbonyl)amino]-1-benzothiophene-2-carboxamide;
- E-25o: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(4-methoxy-3-(trifluoromethyl)phenyl)amino]carbonyl)amino]-1-benzothiophene-2-carboxamide;
- E-25p: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(3-methoxyphenyl)amino]carbonyl)-amino]-1-benzothiophene-2-carboxamide;
- E-25q: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(3-trifluoromethoxyphenyl)amino]-carbonyl)-amino]-1-benzothiophene-2-carboxamide;
- E-25r: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([(tert-butylamino)carbonyl]amino)-1-benzothiophene-2-carboxamide;
- E-25s: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([(cyclohexylamino)carbonyl]amino)-1-benzothiophene-2-carboxamide;
- E-25t: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(1S)-1-phenylethyl]amino]carbonyl-amino)-1-benzothiophene-2-carboxamide;
- E-25u: 7-[(Anilino)carbonyl]amino]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamide;
- E-25v: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-([[(4-methoxyphenyl)amino]carbonyl)-amino]-1-benzofuran-2-carboxamide;
- E-26a: N-[4-(2-Thienyl)phenyl]-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26b: N-[4'-(Hydroxymethyl)-1,1'-biphenyl-4-yl]-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26c: N-(4'-Fluoro-1,1'-biphenyl-4-yl)-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26d: N-(4'-Methylsulfanyl-1,1'-biphenyl-4-yl)-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26e: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(4'-fluoro-1,1'-biphenyl-4-yl)acetamide;
- E-26f: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(4'-methoxy-1,1'-biphenyl-4-yl)acetamide;
- E-26g: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(4'-fluoro-1,1'-biphenyl-3-yl)acetamide;
- E-26h: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(3'-nitro-1,1'-biphenyl-4-yl)acetamide;
- E-26i: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-[4'-(hydroxymethyl)-1,1'-biphenyl-3-yl]acetamide;
- E-26j: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-[4'-(bromomethyl)-1,1'-biphenyl-4-yl]acetamide;
- E-26k: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-[2'-(hydroxymethyl)-1,1'-biphenyl-3-yl]acetamide;
- E-26l: N-[3'-(Acetylamino)-1,1'-biphenyl-4-yl]-2-(1-azabicyclo[2.2.2]oct-3-yl)acetamide;
- E-26m: (3R)-N-[2'-(Hydroxymethyl)-1,1'-biphenyl-4-yl]-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26n: (3R)-N-[4'-(Hydroxymethyl)-1,1'-biphenyl-4-yl]-1-azabicyclo[2.2.2]octane-3-carboxamide;

- E-26o: (3S)-N-[4'-(Hydroxymethyl)-1,1'-biphenyl-4-yl]-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26p: (3R)-N-[4'-(4-Morpholinyl)-1,1'-biphenyl-4-yl]-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26q: (3R)-N-[4'-(Hydroxymethyl)-3'-(methoxy)-1,1'-biphenyl-4-yl]-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26r: Methyl 4'-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylcarbonyl]amino}-1,1'-biphenyl-4-carboxylate;
- E-26s: 4'-{[(3S)-1-Azabicyclo[2.2.2]oct-3-ylcarbonyl]amino}-1,1'-biphenyl-4-carboxylic Acid;
- E-26t: (3R)-N-[4'-(Hydroxy-1-methylethyl)-1,1'-biphenyl-4-yl]-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26u: (3R)-N-[4'-(Aminocarbonyl)-1,1'-biphenyl-4-yl]-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26v: (3R)-N-[4'-(Hydroxymethyl)-3-fluoro-1,1'-biphenyl-4-yl]-1-azabicyclo[2.2.2]octane-3-carboxamide;
- E-26w: (4'-{[(3R)-1-Azabicyclo[2.2.2]oct-3-ylcarbonyl]amino}-1,1'-biphenyl-4-yl)methyl Methylcarbamate;
- E-26x: (4'-{[(3R)-1-Azabicyclo[2.2.2]oct-3-ylcarbonyl]amino}-1,1'-biphenyl-4-yl)methyl Isopropylcarbamate;
- E-26y: (4'-{[(3R)-1-Azabicyclo[2.2.2]oct-3-ylcarbonyl]amino}-1,1'-biphenyl-4-yl)methyl Ethylcarbamate;
- E-26z: the free base form of a compound being selected from Examples No 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35 of WO2003/078431;
- E-27a: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide;
- E-27b: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(6-bromo-1-benzothien-2-yl)acetamide;
- E-27c: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-quinolinyl)acetamide;
- E-27d: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(2-naphthyl)acetamide;
- E-27e: 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(8-nitro-2-naphthyl)acetamide;
- E-28a: N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-quinolinecarboxamide;
- E-28b: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenazinecarboxamide;
- E-28c: N-(1-Azabicyclo[2.2.2]oct-3-yl)-7-quinolinecarboxamide;
- E-28d: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-quinolinecarboxamide;
- E-28e: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-7-quinolinecarboxamide;
- E-28f: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-6-quinolinecarboxamide;

- 20 -

E-28g: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-methyl-7-quinolinecarboxamide;
E-28h: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-methyl-6-quinolinecarboxamide;
E-28i: N-(1-Azabicyclo[2.2.2]oct-3-yl)-4-methyl-6-quinolinecarboxamide;
E-28j: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-propyl-6-quinolinecarboxamide;
E-28k: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-4-methyl-6-quinolinecarboxamide;
E-28l: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-propyl-7-quinolinecarboxamide;
E-28m: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-4-methyl-7-quinolinecarboxamide;
E-28n: N-(1-Azabicyclo[2.2.2]oct-3-yl)-4-(tetrahydro-2H-pyran-2-yl)-6-quinoline-carboxamide;
E-28o: N-(1-Azabicyclo[2.2.2]oct-3-yl)-4-(tetrahydro-2H-pyran-2-yl)-7-quinoline-carboxamide;
E-28p: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenyl-6-quinolinecarboxamide; and
E-28q: N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenyl-7-quinolinecarboxamide;
wherein each of said compound is in free base form or in acid addition salt form.

In one embodiment, the $\alpha 7$ -nAChR agonist is a compound selected from the group consisting of compound A-1, A-2 and A-3; wherein each of said compound is in free base form or in acid addition salt form.

In one embodiment, the $\alpha 7$ -nAChR agonist is a compound selected from the group consisting of compound B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, B-9, B-10, B-11, B-12, B-13, B-14, B-15, B-16, B-17, B-18, B-19, B-20 and B-21; wherein each of said compound is in free base form or in acid addition salt form.

In one embodiment, the $\alpha 7$ -nAChR agonist is a compound selected from the group consisting of compound C-1, C-2, C-3, C-4, C-5, C-6, C-7, C-8, C-9, C-10, C-11 and C-12; wherein each of said compound is in free base form or in acid addition salt form.

In one embodiment, the $\alpha 7$ -nAChR agonist is a compound selected from the group consisting of compound D-1, D-2, D-3 and D-4; wherein each of said compound is in free base form or in acid addition salt form.

In one embodiment, the $\alpha 7$ -nAChR agonist is a compound selected from Group P2; Group P2 is the group consisting of compounds A-1, A-2, A-3, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, B-9, B-10, B-11, B-12, B-13, B-14, B-15, B-16, B-17, B-18, B-19, B-20, B-21, C-1, C-2, C-3, C-4, C-5, C-6, C-7, C-8, C-9, C-10, C-11, C-12, E-1, E-1a, E-1b, E-1c, E-1d, E-2, E-3, E-

- 21 -

3a, E-4, E-4a, E-8, E-8a, E-8b, E-9, E-9a, E-9b, E-10, E-10a, E-11, E-11a, E-11b, E-11c, E-11d, E-11e, E-12, E-19, E-22, E-24, E-24a, E-24b, E-25a, E-25b, E-25c, E-25d, E-25e, E-25f, E-25g, E-25h, E-25i, E-25j, E-25k, E-25l, E-25m, E-25n, E-25o, E-25p, E-25q, E-25r, E-25s, E-25t, E-25u, E-25v, E-28a, E-28b, E-28c, E-28d, E-28e, E-28f, E-28g, E-28h, E-28i, E-28j, E-28k, E-28l, E-28m, E-28n, E-28o, E-28p and E-28q; wherein each of said compound is in free base form or in acid addition salt form.

In one embodiment, the $\alpha 7$ -nAChR agonist is a compound selected from Group P3; Group P3 is the group consisting of compounds A-1, A-2, A-3, B-1, B-2, B-3, B-4, B-5, B-6, B-7, B-8, B-9, B-10, B-11, B-12, B-13, B-14, B-15, B-16, B-17, B-18, B-19, B-20, B-21, C-1, C-2, C-3, C-4, C-5, C-6, C-7, C-8, C-9, C-10, C-11, C-12, E-1, E-1a, E-1b, E-1c, E-1d, E-2, E-3, E-3a, E-4, E-4a, E-8, E-8a, E-8b, E-9, E-9a, E-9b, E-10, E-10a, E-11, E-11a, E-12, E-19, E-22, E-24, E-24a and E-24b; wherein each of said compound is in free base form or in acid addition salt form.

The compounds of formula (I) (e.g. compounds A-1 to A-3, B-1 to B-21 and C-1 to C-12) or compounds of formula (II) (e.g. compounds D-1 to D-4) and their manufacture are known from WO2001/85727, WO2004/022556, WO2005/118535, WO2005/123732, WO2006/005608, WO2007/045478, WO2007/068476 and WO2007/068475, or can be prepared analogously to said references.

Compounds E-1 and E-1a can be prepared according to WO2008/058096.

Compounds E-2, E-3, E-3a, E-4, E-4a and E-5 (A-582941) can be prepared according to WO2005/028477.

Compounds E-6, E-6a, E-7 and E7a can be prepared according to WO2006/065233 and/or WO2007/018738.

Compounds E-8, E-8a, E-8b, E-9, E-9a and E-9b can be prepared according to WO2004/029050 and/or WO2010/043515.

Compounds E-10 and E-10a can be prepared according to WO2004/076449 and/or WO2009/018505;

Compounds E-11, E-11a to E-11e can be prepared according to WO2004/076449 and/or WO2010/085724 and/or WO2010/056622;

Compounds E-12 (CP-810123) and Compound E-19 (varenicline) are described in O'Donnell et al, J Med Chem, 2010, 53, 1222-1237.

- 22 -

Compounds E-13 (PNU-282987), E-14 (PHA543613), E-21 (SSR-180771) and E-23 (ABBF) are described in Horenstein et al, Mol Pharmacol, 2008, 74, 1496-1511.

Compounds E-15 (PHA568487), E-16 (WAY-317538), E-17 (WAY-264620), E-20 (AZD-0328) and E-22 (GTS-21) are described in Haydar et al, Current Topics in Medicinal Chemistry, 2010, 10, 144-152.

Compound E-18 (WYE-103914) is described in Ghiron et al, J Med Chem, 2010, 53, 4379-4389.

Compound E-24, E-24a and E-24b are described in WO2007/133155 and/or WO2009/066107.

Compounds E-25a to E-25v are described in WO2004/013136.

Compounds E-26a to E-26z are described in WO2003/078431.

Compounds E-27a to E-27e are described in WO2003/078430.

Compounds E-28a to E-28q are described in WO2003/043991.

A further aspect of the invention concerns the use of a $\alpha 7$ -nAChR agonist for the treatment (whether therapeutic or prophylactic), prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound of formula (I).

A further aspect of the invention concerns the use of a $\alpha 7$ -nAChR agonist for the treatment (whether therapeutic or prophylactic), prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P1.

A further aspect of the invention concerns the use of a $\alpha 7$ -nAChR agonist for the treatment (whether therapeutic or prophylactic), prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P2.

A further aspect of the invention concerns the use of a $\alpha 7$ -nAChR agonist for the treatment (whether therapeutic or prophylactic), prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P3.

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a

- 23 -

therapeutically effective amount of a $\alpha 7$ -nAChR agonist; wherein said $\alpha 7$ -nAChR agonist is a compound of formula (I).

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR agonist; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P1.

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR agonist; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P2.

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR agonist; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P3.

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises (i) diagnosing dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in said subject and (ii) administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR ; wherein said $\alpha 7$ -nAChR agonist is a compound of formula (I).

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises (i) diagnosing dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in said subject and (ii) administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR ; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P1.

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises (i) diagnosing dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in said subject and (ii) administering

- 24 -

to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR ; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P2.

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises (i) diagnosing dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in said subject and (ii) administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR ; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P3.

A further aspect of the invention relates to a pharmaceutical composition comprising a $\alpha 7$ -nAChR agonist for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound of formula (I).

A further aspect of the invention relates to a pharmaceutical composition comprising a $\alpha 7$ -nAChR agonist for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P1.

A further aspect of the invention relates to a pharmaceutical composition comprising a $\alpha 7$ -nAChR agonist for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P2.

A further aspect of the invention relates to a pharmaceutical composition comprising a $\alpha 7$ -nAChR agonist for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P3.

A further aspect of the invention relates to the use of a $\alpha 7$ -nAChR agonist for the manufacture of a medicament for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound of formula (I).

A further aspect of the invention relates to the use of a $\alpha 7$ -nAChR agonist for the manufacture of a medicament for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P1.

- 25 -

A further aspect of the invention relates to the use of a $\alpha 7$ -nAChR agonist for the manufacture of a medicament for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P2.

A further aspect of the invention relates to the use of a $\alpha 7$ -nAChR agonist for the manufacture of a medicament for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P3.

Nicotinic acetylcholine receptor alpha 7 positive allosteric modulator:

As used herein a " $\alpha 7$ -nAChR positive allosteric modulator" is a compound that binds to a receptor comprising a $\alpha 7$ -nAChR subunit in vivo and in vitro and is potentiating the activation of the receptor when its physiological ligand (i.e. acetylcholine) is binding. Potentiation can be measured by the method disclosed in WO2001/85727, i.e. a functional affinity assay at the homomeric alpha 7 nicotinic acetylcholine receptor ($\alpha 7$ nAChR) carried out with a rat pituitary cell line stably expressing the $\alpha 7$ nAChR. As read out, the calcium influx upon stimulation of the receptor compared to acetylcholine-binding alone is used. " $\alpha 7$ -nAChR positive allosteric modulators" according to the invention typically induce calcium influx of at least 200% of the maximal influx evoked by acetylcholine with an EC_{50} value of at least 5000nM; preferred agonists induce calcium influx of at least 300% of the maximal influx evoked by acetylcholine with an EC_{50} value of at least 1000nM; more preferred agonists induce calcium influx of at least 400% of the maximal influx evoked by epibatidine with an EC_{50} value of at least 500nM.

In particular, preferred $\alpha 7$ -nAChR positive allosteric modulators should be well absorbed from the gastrointestinal tract, should be sufficiently metabolically stable and possess favorable pharmacokinetic properties.

Further preferred $\alpha 7$ -nAChR positive allosteric modulators bind in-vivo potently to $\alpha 7$ -nAChRs whilst showing little affinity for other receptors, especially for other nAChRs, e.g. $\alpha 4\beta 2$ nAChR, for muscarinic acetylcholine receptors, e.g. M1, and/or the 5-HT₃ receptor. Further preferred $\alpha 7$ -nAChR positive allosteric modulators cross the blood brain barrier effectively.

- 26 -

Preferred $\alpha 7$ -nAChR positive allosteric modulators should be non-toxic and demonstrate few side-effects.

Furthermore, a preferred $\alpha 7$ -nAChR positive allosteric modulator will be able to exist in a physical form that is stable, non-hygroscopic and easily formulated.

In one embodiment, the $\alpha 7$ -nAChR positive allosteric modulator is selective for a receptor comprising a $\alpha 7$ -nAChR subunit, since such a positive allosteric modulator would be expected to cause fewer side effects than a non-selective positive allosteric modulator to a treated subject. A positive allosteric modulator being selective for a receptor comprising a $\alpha 7$ -nAChR subunit has a functional affinity to such a receptor to a much higher degree, e.g. at least 10-fold affinity difference in EC_{50} value, preferably at least 20-fold, more preferably at least 50-fold, compared to any other nicotinic acetylcholine receptor. To assess the affinity of the $\alpha 7$ -nAChR positive allosteric modulator of the invention on other nicotinic acetylcholine receptors, the method disclosed in WO2001/85727 can be used, i.e. to assess the affinity on human neuronal $\alpha 4\beta 2$ nAChR, a similar functional assay is carried out using a human embryonic kidney cell line stable expressing the human $\alpha 4\beta 2$ subtype and to assess the activity of the compounds of the invention on the "ganglionic subtype" and the "muscle type" of nicotinic receptor, similar functional assays are carried out with a human embryonic kidney cell line stably expressing the human "ganglionic subtype" or a cell line endogenously expressing the human "muscle type" of nicotinic receptors.

In the last 12 years much effort has been focused on developing selective $\alpha 7$ nAChR positive allosteric modulators leading to the discovery of many different chemotypes displaying said selective activity. These efforts are summarized the review from Haydar et al (Current Topics in Medicinal Chemistry, 2010, 10, 144-152), which describes 11 compounds acting as $\alpha 7$ nAChR positive allosteric modulators belonging to seven different chemical families; i.e. XY-4083; PNU-120596, PHA-758454 and NS-1738; PHA-709829; SB-206553; LY-2087101, LY-1078733 and LY-2087133; compound 26; and A-867744 (compound designations taken from Haydar et al). All said 11 compounds described in Haydar et al are incorporated herein by reference. In fact, at least one drug candidate having an $\alpha 7$ nAChR positive allosteric modulator mode of action obtained permission from the U.S. Food and Drug Administration to conduct clinical testing (i.e. XY-4083).

- 27 -

In one embodiment, the $\alpha 7$ -nAChR positive allosteric modulator is a compound selected from the Group P4; Group P4 is the group consisting of compounds

F-1: (Z)-N-(4-Chloro-phenyl)-3-(4-chloro-phenylamino)-2-(3-methyl-isoxazol-5-yl)-acrylamide (XY-4083);

F-2: 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea (PNU-120596);

F-3: 1-(5-Fluoro-2,4-dimethoxy-phenyl)-3-(5-trifluoromethyl-isoxazol-3-yl)-urea (PHA-758454);

F-4: 1-(5-Chloro-2-hydroxy-phenyl)-3-(2-chloro-5-trifluoromethyl-phenyl)-urea (NS-1738);

F-5: 4-(4-Chloro-phenyl)-2-(4-methoxy-phenyl)-5-methyl-2H-pyrazol-3-ylamine (PHA-709829);

F-6: 5-Methyl-3,5-dihydro-2H-pyrrolo[2,3-f]indole-1-carboxylic acid pyridin-3-ylamide (SB-206553);

F-7: [2-(4-Fluoro-phenylamino)-4-methyl-thiazol-5-yl]-thiophen-3-yl-methanone (LY-2087101);

F-8: [2-(4-Fluoro-phenylamino)-4-methyl-thiazol-5-yl]-p-tolyl-methanone (LY-1078733);

F-9: Benzo[1,3]dioxol-5-yl-[2-(4-fluoro-phenylamino)-4-methyl-thiazol-5-yl]-methanone (LY-2087133);

F-10: 4-Naphthalen-1-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonic acid amide; and

F-11: 4-[5-(4-Chloro-phenyl)-2-methyl-3-propionyl-pyrrol-1-yl]-benzenesulfonamide (A-867744);

wherein said compound is in free base form or in acid addition salt form.

A further aspect of the invention concerns the use of a $\alpha 7$ -nAChR positive allosteric modulator for the treatment (whether therapeutic or prophylactic), prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR positive allosteric modulator is a compound selected from the Group P4.

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR positive allosteric modulator; wherein said $\alpha 7$ -nAChR positive allosteric modulator is a compound selected from the Group P4.

- 28 -

A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises (i) diagnosing dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in said subject and (ii) administering to said subject a therapeutically effective amount of a $\alpha 7$ -nAChR positive allosteric modulator; wherein said $\alpha 7$ -nAChR positive allosteric modulator is a compound selected from the Group P4.

A further aspect of the invention relates to a pharmaceutical composition comprising a $\alpha 7$ -nAChR positive allosteric modulator for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR positive allosteric modulator is a compound selected from the Group P4.

A further aspect of the invention relates to the use of a $\alpha 7$ -nAChR positive allosteric modulator for the manufacture of a medicament for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease; wherein said $\alpha 7$ -nAChR positive allosteric modulator is a compound selected from the Group P4.

The acid addition salt of $\alpha 7$ -nAChR agonists or $\alpha 7$ -nAChR positive allosteric modulators are preferably pharmaceutically acceptable salts. Such salts are known in the field (e.g. S.M. Berge, et al, "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66:1-19; and "Handbook of Pharmaceutical Salts, Properties, Selection, and Use", Stahl, R.H., Wermuth, C.G., Eds.; Wiley-VCH and VHC: Zurich, 2002). A "pharmaceutically acceptable salt" is intended to mean a salt of a free base of a $\alpha 7$ -nAChR agonist or $\alpha 7$ -nAChR positive allosteric modulator that is not toxic, biologically intolerable, or otherwise biologically undesirable. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.

Dyskinesia associated with dopamine agonist therapy:

"Dopamine agonist therapy" is generally used in the treatment of Parkinson's Disease. The term "dopamine agonist therapy" as used herein, unless indicated otherwise, means any therapy that increases dopamine receptor stimulation, including, but not limited to, therapies

- 29 -

that directly stimulate dopamine receptors (such as administration of bromocriptine) and therapies that increase the levels of dopamine (such as administration of levodopa or of drugs which inhibit dopamine metabolism).

Dopamine agonist therapies include, but are not limited to, therapies which comprise the administration of one or more of the following agents:

levodopa (or L-dopa being a precursor of dopamine);

levodopa in combination with a levodopa decarboxylase inhibitor, such as carbidopa or benserazide;

levodopa in combination with a catechol-O-methyl transferase inhibitor, such as tolcapone or entacapone;

a monoamine oxidase B-inhibitor, such as selegiline or rasagiline;

a dopamine receptor agonist, such as bromocriptine, pergolide, pramipexole, ropinirole, cabergoline, apomorphine or lisuride.

The term "dopamine agonist" as used herein, unless otherwise indicated, means any agent that increases dopamine receptor stimulation. Preferred dopamine agonists are levodopa; levodopa in combination with a levodopa decarboxylase inhibitor; levodopa in combination with a catechol-O-methyl transferase inhibitor; a monoamine oxidase B-inhibitor and a dopamine receptor agonist.

In one embodiment of the invention, the therapy comprises the administration of levodopa. Due to prevalence of associated dyskinesia, the daily dosage of levodopa for an effective dopamine agonist therapy of Parkinson's Disease needs to be determined for each patient individually and ranges typically from 250 to 1500 mg. Said total daily dose is distributed between 2-6 administrations per day, e.g. 3-6 administrations of 50-100 mg per administration. Usually, the daily dosage of levodopa needed for an effective therapy increases during the course of the therapy.

In one embodiment of the invention, the therapy comprises the administration of levodopa in combination with a levodopa decarboxylase inhibitor, such as carbidopa or benserazide.

The term "dyskinesia associated with dopamine agonist therapy", as used herein, unless otherwise indicated, means any dyskinesia which accompanies, or follows in the course of,

- 30 -

dopamine agonist therapy, or which is caused by, related to, or exacerbated by dopamine agonist therapy, wherein dyskinesia and dopamine agonist therapy are as defined above. Such dyskinesia often, although not exclusively, occurs as a side-effect of said dopamine agonist therapies of Parkinson's Disease.

Characteristics of such dyskinesias include motor impairment, e.g. the appearance of slow and uncoordinated involuntary movements, shaking, stiffness and problems walking.

For example, patients treated with levodopa often have reduced symptoms of Parkinson's disease but they experience increasing difficulties to remain standing or even sitting. After prolonged use of levodopa, a majority of patients develop such dyskinesia. Dyskinesia can occur at any time during the cycle of treatment with levodopa.

In one embodiment, the $\alpha 7$ -nAChR agonists or $\alpha 7$ -nAChR positive allosteric modulators are for the treatment of dyskinesia, wherein the therapy comprises administration of levodopa, and said dyskinesia occurs at the time of peak levodopa plasma concentrations in the patient.

In one embodiment, the $\alpha 7$ -nAChR agonists or $\alpha 7$ -nAChR positive allosteric modulators are for the treatment of dyskinesia, wherein the therapy comprises administration of levodopa, and said dyskinesia occurs when the levodopa plasma concentrations in a patient rise or fall (diphasic dyskinesia).

Surprisingly it was found that $\alpha 7$ -nAChR agonists and/or positive allosteric modulators are able to prolong the action of dopamine agonists, e.g. levodopa. Consequently, compared to therapies using such dopamine agonists, the time interval for administration of said dopamine agonists may be prolonged leading to a lower daily dosage needed to achieve equal control of Parkinson's Disease.

A further aspect of the invention relates to a method for the treatment or delay of progression of Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of (i) a dopamine agonist and (ii) a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator,

- 31 -

wherein the daily dosage of the dopamine agonist is reduced compared to the daily dosage of said dopamine agonist needed to reach an equal control of Parkinson's Disease in the subject without co-administration of the $\alpha 7$ -nAChR agonist or the $\alpha 7$ -nAChR positive allosteric modulator.

In a preferred embodiment, said dopamine agonist comprises levodopa.

In a further preferred embodiment, said reduced daily dosage is a dosage reduced by at least 10%.

In a further preferred embodiment, said reduced daily dosage is a dosage reduced by at least 20%.

In a further preferred embodiment, said reduced daily dosage is achieved by administering the dopamine agonist in larger time intervals.

Treatment may comprise a reduction in the characteristics associated with dyskinesia, including for example, although not limited to, a reduction in the scale of involuntary movements, a reduction in the number of involuntary movements, an improvement in the ability to carry out normal tasks, an improved ability to walk, increased period of time between episodes of dyskinesia.

One aspect of the treatment of dyskinesias associated with dopamine agonist therapy in Parkinson's Disease is that said treatment should have a minimal adverse effect on the treatment of Parkinson's Disease itself, which is effected by the dopamine agonist therapy. For example: neuroleptics, which can be used to treat dyskinesias, have an adverse effect on the efficiency of the dopamine agonist therapy, for example in parameters associated with cognition, depression and sleep behavior of Parkinson's Disease patients. Highly relevant would be an anti-dyskinetic agent that has a positive effect on the treatment of Parkinson's Disease itself, e.g. improving parameters associated with cognition.

In the case of prophylactic treatment, the $\alpha 7$ -nAChR agonists or $\alpha 7$ -nAChR positive allosteric modulators may be used to delay or prevent the onset of dyskinesia.

The term "subject" as used herein refers preferably to a human being, especially to a patient being diagnosed with Parkinson's Disease.

- 32 -

The term "therapeutically effective amount" as used herein typically refers to a drug amount which, when administered to a subject, is sufficient to provide a therapeutic benefit, e.g. is sufficient for treating, preventing or delaying the progression of dyskinesias associated with dopamine agonist therapy (e.g. the amount provides an amelioration of symptoms, e.g. it leads to a reduction in the scale of involuntary movements).

For the above-mentioned indications (the conditions and disorders) the appropriate dosage will vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.01 to about 100 mg/kg body weight, preferably from about 0.1 to about 10 mg/kg body weight, e.g. 1 mg/kg. In larger mammals, for example humans, an indicated daily dosage is in the range from about 0.1 to about 1000 mg, preferably from about 1 to about 400 mg, most preferably from about 3 to about 100 mg of a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator conveniently administered, for example, in divided doses up to four times a day.

Pharmaceutical Compositions:

For use according to the invention, the $\alpha 7$ -nAChR agonist or $\alpha 7$ -nAChR positive allosteric modulator may be administered as single active agent or in combination with other active agents, in any usual manner, e.g. orally, for example in the form of tablets or capsules, parenterally, for example in the form of injection solutions or suspensions, or transdermally, for example in the form of a patch.

In one embodiment, the manner of administration is oral administration, for example in the form of tablets or capsules.

In one embodiment, the manner of administration is transdermal administration, for example in the form of a patch.

Moreover, the present invention provides a pharmaceutical composition comprising a $\alpha 7$ -nAChR agonist or $\alpha 7$ -nAChR positive allosteric modulator in association with at least one pharmaceutical carrier or diluent for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease. Such

- 33 -

compositions may be manufactured in conventional manner. Unit dosage forms may contain, for example, from about 2.5 to about 25 mg of one or more of the $\alpha 7$ -nAChR agonist or $\alpha 7$ -nAChR positive allosteric modulator.

The pharmaceutical compositions according to the invention are compositions for enteral, such as nasal, rectal or oral; parenteral, such as intramuscular or intravenous; or transdermal (e.g. by a patch) administration to warm-blooded animals (human beings and animals) that comprise an effective dose of the pharmacological active ingredient alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of warm-blooded animal, body weight, age and individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.

The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragées, tablets or capsules.

The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes. Such processes are exemplified in WO 2005/079802, WO 2003/047581, WO 2004/000316, WO 2005/044265, WO 2005/044266, WO 2005/044267, WO 2006/114262 and WO 2007/071358.

Compositions for transdermal administration are described in Remington's Pharmaceutical Sciences 16th Edition Mack; Sucker, Fuchs and Spieser, Pharmazeutische Technologie, 1st Edition, Springer.

Combinations:

The invention also provides a combination comprising (A) a $\alpha 7$ -nAChR agonist or $\alpha 7$ -nAChR positive allosteric modulator; and
(B) at least one of levodopa, a levodopa decarboxylase inhibitor, a catechol-O-methyl transferase inhibitor, a monoamine oxidase B-inhibitor or a dopamine receptor agonist.

- 34 -

A further aspect of the invention concerns a combination comprising (A) a $\alpha 7$ -nAChR agonist; and (B) at least one of levodopa, a levodopa decarboxylase inhibitor, a catechol-O-methyl transferase inhibitor, a monoamine oxidase B-inhibitor or a dopamine receptor agonist; wherein said $\alpha 7$ -nAChR agonist is a compound of formula (I).

A further aspect of the invention concerns a combination comprising (A) a $\alpha 7$ -nAChR agonist; and (B) at least one of levodopa, a levodopa decarboxylase inhibitor, a catechol-O-methyl transferase inhibitor, a monoamine oxidase B-inhibitor or a dopamine receptor agonist; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P1.

A further aspect of the invention concerns a combination comprising (A) a $\alpha 7$ -nAChR agonist; and (B) at least one of levodopa, a levodopa decarboxylase inhibitor, a catechol-O-methyl transferase inhibitor, a monoamine oxidase B-inhibitor or a dopamine receptor agonist; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P2.

A further aspect of the invention concerns a combination comprising (A) a $\alpha 7$ -nAChR agonist; and (B) at least one of levodopa, a levodopa decarboxylase inhibitor, a catechol-O-methyl transferase inhibitor, a monoamine oxidase B-inhibitor or a dopamine receptor agonist; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P3.

Preferably, the combination is a pharmaceutical composition or a combined pharmaceutical preparation.

In this pharmaceutical composition, the combination partners i.e.

(A) the $\alpha 7$ -nAChR agonist or the $\alpha 7$ -nAChR positive allosteric modulator, and

(B) at least one of

- i) levodopa, or
- ii) a dopa decarboxylase inhibitor, or
- iii) a catechol-O-methyl transferase inhibitor, or
- iv) a monoamine oxidase B-inhibitor, or
- iv) a dopamine agonist

can be administered together, one after the other or separately in one combined unit dosage form or in two separate unit dosage forms. The unit dosage form may also be a fixed combination.

As used herein, the term "combinations" shall be taken to mean one or more substances which can be administered together, one after the other or separately in one combined unit

dosage form or in two separate unit dosage forms.

Administration of the dosage forms may be co-dominantly, simultaneously, part-simultaneously, separately or sequentially. The dosage forms of the combination may not necessarily be of the same dosage form and may comprise one or more of:

Enteral: Oral (capsule, tablet, solution), Rectal (suppository)

Parenteral: Intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intramammary injection

Respiratory: Inhalation, Intranasal, Intratracheal

Topical: Mucous membrane application, skin application.

In addition, the release profiles of the medicaments may not be the same, for example one or more component of the combination may be of extended release form.

In one embodiment of the invention a specific combination is used. Said combination comprises:

(A) a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator; and

(B) at least one active agent selected from the group consisting of levodopa, carbidopa, benserazide, tolcapone, entacapone, bromocriptine, pergolide, pramipexole, ropinirole, cabergoline, apomorphine and lisuride.

A further aspect of the invention concerns a combination comprising: (A) a $\alpha 7$ -nAChR agonist; and (B) at least one active agent selected from the group consisting of levodopa, carbidopa, benserazide, tolcapone, entacapone, bromocriptine, pergolide, pramipexole, ropinirole, cabergoline, apomorphine and lisuride; wherein said $\alpha 7$ -nAChR agonist is a compound of formula (I).

A further aspect of the invention concerns a combination comprising: (A) a $\alpha 7$ -nAChR agonist; and (B) at least one active agent selected from the group consisting of levodopa, carbidopa, benserazide, tolcapone, entacapone, bromocriptine, pergolide, pramipexole, ropinirole, cabergoline, apomorphine and lisuride; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P1.

A further aspect of the invention concerns a combination comprising: (A) a $\alpha 7$ -nAChR agonist; and (B) at least one active agent selected from the group consisting of levodopa, carbidopa, benserazide, tolcapone, entacapone, bromocriptine, pergolide, pramipexole,

- 36 -

ropinirole, cabergoline, apomorphine and lisuride; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P2.

A further aspect of the invention concerns a combination comprising: (A) a $\alpha 7$ -nAChR agonist; and (B) at least one active agent selected from the group consisting of levodopa, carbidopa, benserazide, tolcapone, entacapone, bromocriptine, pergolide, pramipexole, ropinirole, cabergoline, apomorphine and lisuride; wherein said $\alpha 7$ -nAChR agonist is a compound selected from the Group P3.

In one embodiment of the invention a specific combination is used. Said combination comprises:

- (A) a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator; and
- (B) levodopa and at least one active agent selected from the group consisting of carbidopa, benserazide, tolcapone, entacapone, bromocriptine, pergolide, pramipexole, ropinirole, cabergoline, apomorphine or lisuride.

An example of said embodiment is a combination of a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator with levodopa which may further comprise a levodopa decarboxylase inhibitor, such as carbidopa or benserazide.

An example of said embodiment is a combination of a $\alpha 7$ -nAChR agonist selected from the Group P3 with levodopa which further comprises a levodopa decarboxylase inhibitor, such as carbidopa.

An example of said embodiment is a combination of a $\alpha 7$ -nAChR agonist selected from the Group P3 with levodopa which further comprises a levodopa decarboxylase inhibitor, such as benserazide.

In one embodiment of the invention a specific combination is used. Said combination comprises:

- (A) a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator; and
- (B) levodopa; carbidopa and entacapone.

An example of said embodiment is a combination of a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator with Stalevo®.

An example of said embodiment is a combination of a $\alpha 7$ -nAChR agonist selected from the Group P3 with Stalevo®.

- 37 -

The invention also provides a product, for example a kit, comprising a $\alpha 7$ -nAChR agonist or $\alpha 7$ -nAChR positive allosteric modulator and levodopa as a combined preparation for simultaneous, separate or sequential use in therapy. The product may further comprise a levodopa decarboxylase inhibitor, such as carbidopa or benserazide.

The usefulness of the $\alpha 7$ -nAChR agonists or $\alpha 7$ -nAChR positive allosteric modulators in the treatment of the above-mentioned disorders can be confirmed in a range of standard tests including those indicated below.

1. In-vitro Tests

1.1. Selectivity of selected $\alpha 7$ -nAChR agonists against $\alpha 4\beta 2$ -nAChR

Based on the activity/selectivity data shown below it is concluded that said compounds are selective agonists at the $\alpha 7$ -nAChR.

Compound	$\alpha 7$ -nAChR activity		$\alpha 4\beta 2$ -nAChR activity		fold selectivity
	Potency EC ₅₀ (nM)	Efficacy compared to epibatidine (100%)	IC ₅₀ (nM)	EC ₅₀ (nM)	
A-1	100	83	23442	>100 000	234
C-1	24	84	9333	>100 000	388
B-13	13	89	4217	>100 000	324

Assay: To assess $\alpha 7$ -nAChR activity, a functional assay was employed using GH3 cells that recombinantly expressed human $\alpha 7$ -nAChR. 50000 cells per well were seeded 72 h prior to the experiment on black 96-well plates (Costar) and incubated at 37°C in a humidified atmosphere (5 % CO₂/95 % air). On the day of the experiment, medium was removed by flicking the plates and replaced with 100 μ l growth medium containing 2 mM Fluo-4, (Molecular Probes) in the presence of 2.5 mM probenecid (Sigma). The cells were incubated at 37°C in a humidified atmosphere (5 % CO₂/95 % air) for 1 h. Plates were flicked to remove excess of Fluo-4, washed twice with Hepes-buffered salt solution (in mM: NaCl 130, KCl 5.4, CaCl₂ 2, MgSO₄ 0.8, NaH₂PO₄ 0.9, glucose 25, Hepes 20, pH 7.4; HBS) and refilled with 100 μ l of HBS containing antagonist when appropriate. The incubation in the presence of the antagonist lasted 3-5 minutes. Plates were placed in the cell plate stage of a FLIPR device (fluorescent imaging plate reader, Molecular Devices, Sunnyvale, CA, USA). After recording of the baseline (laser: excitation 488 nm at 1 W, CCD camera opening of 0.4 seconds) the agonists (50 μ l) were added to the cell plate using the FLIPR 96-tip pipettor while simultaneously recording the fluorescence. Calcium kinetic data were normalized to

the maximal fitted response induced by epibatidine, which is a full agonist at $\alpha 7$ -nAChR. Four parameter Hill equations were fitted to the concentration-response. Values of E_{max} (maximal effect in % compared to the epibatidine response) and EC_{50} (concentration producing half the maximal effect in μM) were derived from this fit.

Assay described in: D Feuerbach et al, Neuropharmacology (2005), 48, 215-227.

To assess the activity of the compound of the invention on the human neuronal nAChR $\alpha 4\beta 2$, a similar functional assay is carried out using a human epithelial cell line stably expressing the human $\alpha 4\beta 2$ subtype (Micheltore et al., Naunyn-Schmiedeberg's Arch. Pharmacol. (2002) 366, 235).

2. In-vivo Preclinical Tests

2.1. Oral bioavailability and brain penetration in Mice

Based on the pharmacokinetic data shown below it is concluded that the brain concentration of said compounds in mice is beyond (or at least equal) to the compound's EC_{50} at the $\alpha 7$ -nAChR for at least 4 hours following an acute oral dose of 30 $\mu mol/kg$.

Compound A-1:

Administration	Time (hour)	Plasma (pmoles/ml $\pm$ SD)	Brain (pmoles/g $\pm$ SD)	Ratio Brain/plasma
30 $\mu mol/kg$ p.o.	0.5	634.9 $\pm$ 261.3	706.3 $\pm$ 153.4	1.1
30 $\mu mol/kg$ p.o.	1	684.7 $\pm$ 339.6	573.7 $\pm$ 109.3	0.8
30 $\mu mol/kg$ p.o.	2	168.2 $\pm$ 91.3	191.9 $\pm$ 34.9	1.1
30 $\mu mol/kg$ p.o.	4	85.0 $\pm$ 54.3	104.6 $\pm$ 39.6	1.2
30 $\mu mol/kg$ p.o.	6	29.5 $\pm$ 13.8	40.5 $\pm$ 12.1	1.4
30 $\mu mol/kg$ p.o.	24	3.8 $\pm$ 0.6	9.1 $\pm$ 2.7	2.4

Compound B-13:

Administration	Time (hour)	Plasma (pmoles/ml $\pm$ SD)	Brain (pmoles/g $\pm$ SD)	Ratio Brain/plasma
30 $\mu mol/kg$ p.o.	0.25	2196 $\pm$ 397	1884 $\pm$ 291	0.86
30 $\mu mol/kg$ p.o.	0.5	2265 $\pm$ 419	2960 $\pm$ 706	1.31
30 $\mu mol/kg$ p.o.	1	1554 $\pm$ 523	2940 $\pm$ 335	1.89
30 $\mu mol/kg$ p.o.	2	1172 $\pm$ 252	1260 $\pm$ 172	1.07
30 $\mu mol/kg$ p.o.	4	429 $\pm$ 167	379 $\pm$ 134	0.88
30 $\mu mol/kg$ p.o.	8	80 $\pm$ 23	93 $\pm$ 30	1.17
30 $\mu mol/kg$ p.o.	24	*	13 $\pm$ 4	

Compound C-1:

Administration	Time (hour)	Plasma (pmoles/ml $\pm$ SD)	Brain (pmoles/g $\pm$ SD)	Ratio Brain/plasma
30 $\mu mol/kg$ p.o.	0.25	1601 $\pm$ 758	620 $\pm$ 221	0.39
30 $\mu mol/kg$ p.o.	0.5	3414 $\pm$ 956	1405 $\pm$ 539	0.41
30 $\mu mol/kg$ p.o.	1	1241 $\pm$ 583	1458 $\pm$ 189	1.17

- 39 -

30 µmol/kg p.o.	2	875 ± 261	1478 ± 259	1.69
30 µmol/kg p.o.	4	762 ± 159	842 ± 187	1.11
30 µmol/kg p.o.	8	239 ± 27	362 ± 62	1.51
30 µmol/kg p.o.	24	*	*	

Assay: Compounds were orally (30 µmol/kg) administered. Male mice (30-35g, OF1/ICstrain) were sacrificed at indicated time points after oral administration. Trunk- blood was collected in EDTA-containing tubes and the brain was removed and immediately frozen on dry ice. To 100 µl plasma 10 µl internal standard (1.0 pmol of a compound with solubility and ionization properties similar to test compounds) was added and extracted three times with 500 µl dichloromethane. The combined extracts were then dried under a stream of nitrogen and re-dissolved in 100 µl acetonitrile/water (70% acetonitrile). Brains were weighed and homogenized in water (1:5 w/v). Two 100 µl aliquots of each homogenate + 10 µl of internal standard (same standard as used for the plasma samples) were extracted three times with 500 µl dichloromethane and further processed as the plasma samples. Samples were separated on Beckmann high-performance liquid chromatography equipment system with an autosampler (Gilson 233XL). A 10 min linear gradient (10 - 70%) of acetonitrile containing 0.5 % (v/v) formic acid was used to elute the compounds from Nucleosil CC-125/2 C18 reversed phase (Machery&Nagel) column.

The limit of detection (LOD), defined as the lowest concentration of the extracted standard sample with a signal to noise ratio of ~ 3.

2.2. Functional read-out in Mice (Social Recognition Test)

Based on the functional in-vivo data shown below it is concluded that oral dosing of said compounds at relevant concentrations lead to a specific effect associated with α7-nAChR (i.e. cognition enhancement in the Social Recognition Test in mouse).

Compound	Reduction in time scrutinizing in % ± SEM at 24 h	Dose in mg/kg
A-1	52 ± 4	3
C-1	51 ± 3	0.3
B-13	37 ± 7	0.3

Assay: Social interactions between two experimental animals are influenced by their degree of familiarity: the better they know each other, the less time they spend on mutual scrutiny at each meeting. In agreement with published data in rats (Mondadori et al., 1993) we have observed (i) that an adult mouse shows a shortened scrutiny of a young conspecific if the two mice are brought together again within a short time interval (e.g. 1 hour), (ii) that this

- 40 -

curtailment is attributable to memory processes: it does not occur if the familiar young partner is replaced by a strange (unfamiliar) young mouse on the second occasion and (iii) that the adult mouse's recollection of the previously scrutinized juvenile partner fades with the elapsed time, i.e., after 24 h, scrutiny takes just about as long as at the first encounter. Memory enhancing agents (i.e. oxiracetam) facilitate learning to the extent that the previously met (familiar) partner is still remembered after 24 h, whereas in vehicle treated control animals the memory usually fades after less than 1 hour (Thor and Holloway, 1982) or after 2-3 hours.

Baseline-test: Pairs consisting of one adult and one young mouse were assigned at random to the experimental and control groups. In each pair only the adult mouse was orally treated 1 hour before the trial with either vehicle or the test compound. The duration of active contacts of the adult mouse with the young mouse was manually recorded over a period of 3 min, including the following behavioural, approach-related items: sniffing, nosing, grooming, licking, pawing and playing, anogenital exploration and orientation toward the young mouse; orientation, thereby, was defined as tip of nose of the adult mouse less than approximately 1cm distant from the young mouse's body.

Re-test: Twenty-four hours after the baseline-test, the adults in each treatment group were confronted again with the previously encountered (familiar) partner, whereas the half of the adult animals were put together with the previously encountered (familiar) partner and the other half with another (unfamiliar) young mouse. Again the duration of active approach-behaviours was recorded during a 3-min period. Prior to re-test no oral injection was given. In the table the reduction in time scrutinizing the familiar partner at time 24 compared with the familiar partner at time 0 minutes is given (value of zero would signify no reduction).

2.3. Assessment of antidyskinetic effect in parkinsonian primates

Based on the in-vivo data in parkinsonian primates shown below it is concluded that compound A-1 does not delay the onset of action of levodopa, does not lower the antiparkinsonian activity of levodopa, significantly reduces the levodopa-induced dyskinesias and significantly increases the duration of the antiparkinsonian activity of levodopa.

2.3.1 Method

Female ovariectomized cynomolgus monkeys (*Macaca fascicularis*) are used in the assessment. The animals can be rendered parkinsonian by continuous infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) until they develop a stable parkinsonian

syndrome. After recuperation, animals are treated daily with levodopa until clear and reproducible dyskinesias are developed.

2.3.2 Assessment

Monkeys are observed through a one-way screen window in their home cage. They are observed and scored repeatedly at baseline and after a standard s.c. dose of levodopa. Locomotor activity is assessed and followed with an electronic monitoring system.

Antiparkinsonian responses are evaluated by measuring the locomotor activity and a Parkinson disability scale (see Hadj Tahar A et al, Clin Neuropharmacol 2000; 23:195-202; and Samadi P et al, Neuropharmacology 2003; 45:954-963). Dyskinesias are closely monitored and scored according to a dyskinesia rating scale (also described in Hadj Tahar A et al; and Samadi P et al) every 15 minutes until the end of the effect. The doses of levodopa are chosen to induce motor activation and reproducible dyskinesia but no excessive agitation.

2.3.3 Protocol

Monkeys are observed for at least two hours following an oral administration of vehicle. On a subsequent day, the dose of levodopa selected is tested once. The animals are observed (with measures of parkinsonian and dyskinetic scores) for the entire duration of the levodopa effect and are also monitored for locomotor activity. This provides vehicle control values as well as levodopa antiparkinsonian and dyskinesia response data for comparison with combinations of a $\alpha 7$ -nAChR agonist/positive allosteric modulator and levodopa. The monkeys are then tested with a $\alpha 7$ -nAChR agonist/positive allosteric modulator in combination with a fixed dose of levodopa. A suspension for oral administration of the $\alpha 7$ -nAChR agonist/positive allosteric modulator is administered before levodopa. After each dose, the animals are observed (with measures of parkinsonian and dyskinetic scores) for the entire duration of effect and monitored for locomotor activity or any change in behavior (e.g. circling, excitement, lethargy and sleepiness).

Using this protocol, compound A-1 at a dose of 20 mg/kg was tested. Results based on five monkeys (levodopa/benserazide doses: 22.5/50 mg; 65/50 mg; 30/50 mg; 35/50 mg; and 25/50 mg) are shown in Figures 1-4. In said experiments, compound A-1 reduced the Mean Dyskinesia Score (total period) from 2.8 to 2.1; furthermore, compound A-1 extended the Duration of Levodopa-Response from 230 minutes to 265 minutes. Neither Elapsed Time after Levodopa Administration or extent of the antiparkinsonian activity of Levodopa

- 42 -

measured with the antiparkinsonian score were changed significantly with the addition of compound A-1.

2. Clinical Testing: Improvement Trials

Clinical testing of the $\alpha 7$ -nAChR agonist/positive allosteric modulator may be conducted, for example, in one of the following study designs. The skilled physician may look at a number of aspects of patient behaviors and abilities. He will realize that such studies are considered as guidelines and the certain aspects of the studies may be modified and redefined depending on the circumstance and environment, for example.

2.1 Trial A: Normal Patient Population

A patient population, with a normal control is dosed once a day for a week or longer tested. The test is designed to allow for improvement, i.e. that there is a measurable parameter increase of the impaired function. The patients are tested at the beginning and at the end of the dosage period and the results are compared and analyzed.

2.2 Trial B: Deficit population

A patient population with a deficit associated with Parkinson's Disease and associated disorders e.g. Parkinson's dyskinesia, for example, Parkinson's Disease levodopa induced Parkinson's dyskinesia is dosed once a day for a week or longer and tested. The test is designed to allow for improvement, i.e. that there is a measurable parameter increase of the impaired function. The patients are tested at the beginning and at the end of the dosage period and the results are compared and analyzed.

2.3 Considerations for designing a trial

- When designing a trial, the skilled person will appreciate the need to protect both against floor and ceiling effects. In other words, the study designing should allow cognition to the measurably raised or lowered.
- Conditions that artificially impair a function, e.g. cognition, are one way to test enhancement of that function. Such conditions are, for example, sleep deprivation and pharmacological challenges.
- Placebo control is required for all trials.

- 43 -

- In assessing the data, evaluation of the likelihood of learning and practice effects from repeat assessments must be made. The likelihood of such effects contaminating the data to produce false positives should be taken in to account when designing the test, e.g. the tests should not be identical (e.g. commit the same list of words to memory) but designed to study the same mechanism. Other countermeasures may include single testing at the end of a trial only.

Description of Figures:

Figure 1: Elapsed time after L-dopa administration for behavioural response in parkinsonian primates

Figure 2: Mean Parkinsonian Score (total period) after L-dopa administration in parkinsonian primates

Figure 3: Mean Dyskinesia Score (total period) after L-dopa administration in parkinsonian primates

Figure 4: Duration of L-dopa response after L-dopa administration in parkinsonian primates

CLAIMS

1. A nicotinic acetylcholine receptor alpha 7 agonist or a nicotinic acetylcholine receptor alpha 7 positive allosteric modulator for use in the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
2. A nicotinic acetylcholine receptor alpha 7 agonist for use in the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
3. A compound according to any of claims 1 or 2, wherein the therapy comprises the administration of levodopa.
4. A method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a nicotinic acetylcholine receptor alpha 7 agonist or a nicotinic acetylcholine receptor alpha 7 positive allosteric modulator.
5. A method for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a nicotinic acetylcholine receptor alpha 7 agonist.
6. A method according to claims 4 or 5, wherein the therapy comprises the administration of levodopa.
7. A method for the treatment or delay of progression of Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of (i) a dopamine agonist and (ii) a $\alpha 7$ -nAChR agonist or a $\alpha 7$ -nAChR positive allosteric modulator,
wherein the daily dosage of the dopamine agonist is reduced compared to the daily dosage of said dopamine agonist needed to reach an equal control of Parkinson's Disease in the

- 45 -

subject without co-administration of the $\alpha 7$ -nAChR agonist or the $\alpha 7$ -nAChR positive allosteric modulator.

8. A method according to claim 7, wherein the dopamine agonist comprises levodopa.

9. A pharmaceutical composition comprising a nicotinic acetylcholine receptor alpha 7 agonist or a nicotinic acetylcholine receptor alpha 7 positive allosteric modulator for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

10. A pharmaceutical composition comprising a nicotinic acetylcholine receptor alpha 7 agonist for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

11. A composition according to claims 9 or 10, wherein the therapy comprises the administration of levodopa.

12. A combination comprising (A) a nicotinic acetylcholine receptor alpha 7 agonist or nicotinic acetylcholine receptor alpha 7 positive allosteric modulator; and (B) at least one of levodopa, a levodopa decarboxylase inhibitor, a catechol-O-methyl transferase inhibitor, a monoamine oxidase B-inhibitor or a dopamine receptor agonist.

13. A combination comprising (A) a nicotinic acetylcholine receptor alpha 7 agonist; and (B) at least one of levodopa, a levodopa decarboxylase inhibitor, a catechol-O-methyl transferase inhibitor, a monoamine oxidase B-inhibitor or a dopamine receptor agonist.

14. A pharmaceutical composition comprising (A) a nicotinic acetylcholine receptor alpha 7 agonist or a nicotinic acetylcholine receptor alpha 7 positive allosteric modulator; and (B) at least one of levodopa, a levodopa decarboxylase inhibitor, a catechol-O-methyl transferase inhibitor, a monoamine oxidase B-inhibitor or a dopamine receptor agonist.

15. A pharmaceutical composition comprising (A) a nicotinic acetylcholine receptor alpha 7 agonist; and (B) at least one of levodopa, a levodopa decarboxylase inhibitor, a catechol-O-

- 46 -

methyl transferase inhibitor, a monoamine oxidase B-inhibitor or a dopamine receptor agonist.

1/4

Elapsed time after L-Dopa administration
for behavioral response






Figure 1

2/4


Figure 2

3/4

Figure 3

4/4

Duration of L-Dopa response



*** $P < 0.001$ vs L-Dopa alone

Figure 4

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/063946

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/198 A61P25/14 A61P25/15

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/048294 A1 (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; KALKMAN HANS O [CH]; NOZU) 11 May 2006 (2006-05-11) claims 1,14 page 9, paragraph 4	12-15
X	EP 1 977 746 A1 (PARKINSON S INST [US]) 8 October 2008 (2008-10-08) claims 1-15 ----- -/--	1-15

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 November 2010

Date of mailing of the international search report

12/01/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040.
Fax: (+31-70) 340-3016

Authorized officer

Albayrak, Timur

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/063946

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	QUIK MARYKA ET AL: "Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys" ANNALS OF NEUROLOGY, vol. 62, no. 6, 1 December 2007 (2007-12-01), pages 588-596, XP002489587 JOHN WILEY AND SONS, BOSTON, US ISSN: 0364-5134 DOI: 10.1002/ANA.21203 the whole document	1-15
Y	WO 2006/067611 A1 (PFIZER PROD INC [US]; GROPPI VINCENT EDWARD JR [US]; HURST RAYMOND STU) 29 June 2006 (2006-06-29) page 8, line 18 - line 19 page 2, line 9 - line 11 example 4	1-15
X	US 2007/254921 A1 (SELLERS EDWARD [CA] ET AL) 1 November 2007 (2007-11-01) paragraph [0025] claim 26	12-15
T	FINBERG J P M ET AL: "Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat" BRITISH JOURNAL OF PHARMACOLOGY, vol. 149, no. 6, November 2006 (2006-11), pages 647-656, XP002608662 ISSN: 0007-1188	1-15
X	US 2003/073715 A1 (EL-RASHIDY RAGAB [US] ET AL) 17 April 2003 (2003-04-17) table v	12-15
X	WO 02/100858 A2 (UPJOHN CO [US]; WALKER DANIEL P [US]; WISHKA DONN G [US]; CORBETT JEFF) 19 December 2002 (2002-12-19) claim 79	1-15
X	WO 2007/110730 A2 (PFIZER PROD INC [US]; BRONK KAREN SROUR [US]; BUSCH FRANK ROBERT [US];) 4 October 2007 (2007-10-04) claim 4	1-15
X	WO 2004/108668 A2 (TARGACEPT INC [US]; BENCHERIF MEROUANE [US]; MILLER CRAIG HARRISON [US]) 16 December 2004 (2004-12-16) claim 29	1-15
	----- -/--	

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/063946

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/051394 A1 (PFIZER PROD INC [US]; DUPLANTIER ALLEN JACOB [US]; KHASANOV ALISHER BA) 18 May 2006 (2006-05-18) claim 12 -----	1-15
Y,P	QUIK M ET AL: "nAChR agonists reduce L-dopa-induced dyskinesias in parkinsonian rats" BIOCHEMICAL PHARMACOLOGY, vol. 78, no. 7, October 2009 (2009-10), page 922, XP002611505 SYMPOSIUM ON NICOTINIC ACETYLCHOLINE RECEPTORS AS THERAPEUTIC TARGETS; CHICAGO, IL, USA; ISSN: 0006-2952 the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2010/063946

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006048294	A1	11-05-2006	
		AU 2005300691 A1	11-05-2006
		BR PI0517647 A	14-10-2008
		CA 2582436 A1	11-05-2006
		CN 101039670 A	19-09-2007
		EP 1809285 A1	25-07-2007
		EP 2135609 A1	23-12-2009
		JP 2008518896 T	05-06-2008
		KR 20070073881 A	10-07-2007
		US 2010125063 A1	20-05-2010
		US 2008306081 A1	11-12-2008
EP 1977746	A1	08-10-2008	
		AU 2008232453 A1	09-10-2008
		CA 2682323 A1	09-10-2008
		CN 101772346 A	07-07-2010
		GB 2448224 A	08-10-2008
		GB 2461412 A	06-01-2010
		JP 2010523587 T	15-07-2010
		KR 20100045406 A	03-05-2010
		US 2008260825 A1	23-10-2008
		US 2010029723 A1	04-02-2010
		US 2010166735 A1	01-07-2010
		US 2010158895 A1	24-06-2010
		US 2010196463 A1	05-08-2010
		US 2010159004 A1	24-06-2010
		WO 2008122049 A2	09-10-2008
WO 2006067611	A1	29-06-2006	
		AR 052071 A1	28-02-2007
		CA 2592158 A1	29-06-2006
		EP 1831683 A1	12-09-2007
		JP 2008525785 T	17-07-2008
US 2007254921	A1	01-11-2007	NONE
US 2003073715	A1	17-04-2003	NONE
WO 02100858	A2	19-12-2002	
		AR 036041 A1	04-08-2004
		AU 2002348503 A1	23-12-2002
		CA 2445471 A1	19-12-2002
		EP 1404674 A2	07-04-2004
		JP 2004534065 T	11-11-2004
WO 2007110730	A2	04-10-2007	
		AR 060329 A1	11-06-2008
		AU 2007231072 A1	04-10-2007
		CA 2644448 A1	04-10-2007
		EP 2004186 A2	24-12-2008
		JP 2007262066 A	11-10-2007
		KR 20090005305 A	13-01-2009
		RU 2008138532 A	10-04-2010
WO 2004108668	A2	16-12-2004	
		US 2007185086 A1	09-08-2007
WO 2006051394	A1	18-05-2006	
		AR 051955 A1	21-02-2007
		CA 2587461 A1	18-05-2006
		EP 1814888 A1	08-08-2007
		GT 200500332 A	13-06-2006
		JP 2008519818 T	12-06-2008
		NL 1030418 C2	23-11-2006
		NL 1030418 A1	16-05-2006

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2010/063946

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006051394 A1	UY	29212 A1	30-06-2006